Pluri (NASDAQ:PLUR – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.
Valuation & Earnings
This table compares Pluri and AbCellera Biologics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluri | $1.02 million | 12.86 | -$23.82 million | ($2.65) | -0.39 |
| AbCellera Biologics | $75.13 million | 48.34 | -$146.41 million | ($0.48) | -23.17 |
Pluri has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Pluri and AbCellera Biologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
| AbCellera Biologics | 1 | 1 | 8 | 2 | 2.92 |
AbCellera Biologics has a consensus price target of $16.55, suggesting a potential upside of 48.79%. Given AbCellera Biologics’ stronger consensus rating and higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than Pluri.
Risk & Volatility
Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Insider and Institutional Ownership
16.6% of Pluri shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Pluri and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pluri | -1,943.87% | N/A | -104.36% |
| AbCellera Biologics | -218.54% | -15.35% | -10.84% |
Summary
AbCellera Biologics beats Pluri on 11 of the 15 factors compared between the two stocks.
About Pluri
Pluri Ltd. is an Israel-based biotechnology company developing cell-based products and technologies. Its therapeutic research centers on PLX cells, derived from human placental tissue and expanded using the company’s cell-manufacturing platform. Pluri has investigated these cells for potential use in a range of medical conditions; its therapies remain in development. The company also applies its cell-expansion technology to areas beyond medicine, including food technology and agriculture, where it is exploring cell-based products and production methods.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
